Income-Seeking Investors Weigh Merck Against High-Flying Eli Lilly
Eli Lilly’s rapid ascent on the strength of its weight-loss drugs has dominated pharmaceutical headlines, but a closer look at dividend metrics suggests that Merck may offer a more attractive option for income-oriented investors. On 8 March 2026, market analysts reviewed both companies’ fundamentals, highlighting stark differences in valuation, product concentration and shareholder payouts. GLP-1 […]